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Imperfect vaccineTwo caliciviruses occur in Australian wild rabbits: rabbit calicivirus Australia 1 (RCV-A1) and rabbit
haemorrhagic disease virus (RHDV), which is used in Australia as a biocontrol agent to reduce feral rabbit
populations. There is concern that RCV-A1 acts as a natural vaccine and protects from lethal RHDV infection.
To investigate this hypothesis, domestic rabbits were perorally infected with RCV-A1, monitored for 28 days
and subsequently challenged with RHDV. We show that RCV-A1 causes a non-pathogenic infection and is
shed in faeces for up to 7 days post-infection. RCV-A1 was detected in the bile 2 months post-inoculation,
indicating a prolonged or possible persistent infection. All animals infected with RCV-A1 developed
antibodies cross-reacting to RHDV. When challenged with RDHV, half of the rabbits (n=4) survived the
infection. The results indicate that RCV-A1 is likely to persist in rabbit populations and can elicit partial cross-
protection to lethal RHDV infection.
© 2009 Published by Elsevier Inc.Introduction
Rabbit haemorrhagic disease virus (RHDV) is an extremely
pathogenic member of the genus lagovirus within the family
Caliciviridae (Green et al., 2000). It ﬁrst became apparent in the
mid-1980s when an outbreak of an infectious hepatitis with mortality
rates up to 95% was reported in farmed angora rabbits in China (Liu
et al., 1986). Subsequently, RHDV spread through most parts of the
world, causing damage to the rabbit meat industry worldwide and
decimating wild rabbit populations in Europe (Delibes-Mateos et al.,
2007; McIntosh et al., 2007). Its high level of pathogenicity drew
attention to the virus as a potential biocontrol agent in places where
rabbits are a problem. On the Australian continent, feral European
rabbits are one of the country's worst introduced vertebrate pests,
causing serious economical and environmental damage (Corbet et al.,
1994). Since 1996, RHDV has been used effectively as a biocontrol
agent to keep rabbit numbers low in Australia. In the 13 years
following its release, this has resulted in close to 6 billon dollars worth
of economical savings (Ward et al., in press), and much needed reliefx 1700, Canberra, ACT, 2601,
lsevier Inc.of grazing pressure from rabbits, allowing some regeneration of native
plant species (Cooke, 1988; Sandell, 2002). However, it has been
reported that RHDV is less efﬁcient in controlling rabbits in some
areas of the continent, namely, the more temperate coastal climate
zones (Cooke et al., 2002; Robinson et al., 2002a). In addition,
antibodies cross-reacting to RHDV were found in wild rabbits from
these temperate areas before the virus was released as a biocontrol
agent in 1996 (Nagesha et al., 2000). These ﬁndings resulted in the
hypothesis that a calicivirus related to RHDV is circulating in
Australian wild rabbits (Cooke et al., 2002; Robinson et al., 2002a).
Four different RHDV-speciﬁc ELISAs are normally conducted in
Australian RHDV ﬁeld epidemiology studies, subtype ELISAs for IgM,
IgA and total IgG and a competition ELISA detecting all immune
globulins (Cooke et al., 2000). Rabbits with low-medium titres in the
IgG antibody tests, but with no reaction in the IgA and IgM tests, and
little to no reaction in the cELISA are scored as having cross-reacting
antibodies to this putative related calicivirus (Cooke et al., 2000).
When rabbits classiﬁed as having such cross-reacting antibodies were
challenged with RHDV, survival rates of 30–50% were reported
(McPhee et al., 2009; Nagesha et al., 2000).
Immunological cross-reactivity between related viruses leading to
partial or complete cross-protection is widely known. The most
famous example is vaccinia virus, which is able to convey effective
immunity to other members of the Orthopoxvirus family. This ﬁnding
Fig. 1. Virus shedding of RCV-A1 infected rabbits. Quantitative RT-PCR was used to
monitor RCV-A1 RNA during the course of infection in (A) faeces, (B) rectal swabs and
(C) whole blood. Individual values, means and standard deviations are depicted. The
number of animals at each time point is indicated. The dotted line represents the
detection limit for the respective sample.
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using vaccinia virus inoculation to prevent highly pathogenic variola
virus infection in humans. Cross-reactivity leading to complete
protection has also been described in lagoviruses (Capucci et al.,
1997). The responsible virus termed rabbit calicivirus (RCV) was
identiﬁed in a commercial rabbitry in Italy andwas capable of inducing
an antibody response that completely protected rabbits from rabbit
haemorrhagic disease (Capucci et al., 1996). Several other studies also
reported the isolation of fragments of lagovirus RNA from wild rabbit
tissues, that were different from RHDV and more similar to RCV-It
(Forrester et al., 2009, 2007; Moss et al., 2002). They also inferred
protective properties of these isolates (Forrester et al., 2009);
however, experimental infections with these viruses have yet to be
conducted to demonstrate cross-protection. In contrast, Marchandeau
et al. (2005) suggest circulating benign strains of lagoviruses incapable
of conveying cross-immunoprotectivity, based on the presence of
cross-reacting antibodies in rabbits that had died of RHDV.
Recently, a new lagovirus endemic to Australian wild rabbits was
identiﬁed and designated rabbit calicivirus Australia-1 (RCV-A1). Its
single-stranded plus strand RNA genome of about 7.5 nt length is 85%
identical to that of RHDV, and genome organisation and phylogenetic
analysis ﬁrmly place it within the genus lagovirus (Strive et al., 2009).
There is now signiﬁcant concern that RCV-A1 is the cause of the
observed cross-reacting antibodies and reduction of RDHV-induced
rabbit mortality in certain areas of Australia, and that RCV-A1, similar
to the Italian RCV, may act as a natural vaccine conferring at least
partial immunoprotection from lethal RHDV infection.
Here we describe a study where the biological properties of RCV-
A1 were assessed in experimentally infected domestic rabbits.
Pathogenicity of RCV-A1, tissue tropism, shedding patterns and the
ability to generate an antibody response cross-reacting to RHDV were
investigated. All animals developed antibodies reacting in RHDV-
speciﬁc ELISA tests, and two out of four rabbits previously infected
with RCV-A1 survived the subsequent RHDV challenge infection,
conﬁrming that RCV-A1 is indeed capable of conveying cross-
immunoprotection to RHDV. Notably, RCV-A1 was secreted in the
bile of infected animals 2 months after infection while at the same
time being undetectable in the liver.
The results of this are an important step towards understanding
the epidemiology of RCV-A1 and its interactions with RHDV and will
aid the development of new strategies to improve rabbit management
in Australia. Apart from the immediate applied outcomes, the ﬁndings
of this study once more draw attention to rabbits and their viruses
as an excellent model system to study virus–host and virus–virus
interactions.
Results
RCV-A1 infection
RCV-A1 is a non-pathogenic virus. None of the eight infected
animals showed any signs of disease in the 28 days of the trial and all
rabbits continuously gained weight (data not shown). Body tempera-
tures showed the normal diurnal ﬂuctuations between approximately
38 °C and 40.5 °C, no signs of fever were apparent in any of the
animals infected with RCV-A1. Similar results were observed with the
two rabbits infected for RCV-A1-positive serum production, and no
signs of disease were apparent at any time during the 5 months these
animals were kept.
Virus shedding was observed in the faeces of the treated animals
between days 2 and 7; only on day 4 post-infection, all animals tested
positive (Fig. 1). Rectal swabs tested positive between days 1 and 7; all
animals were positive on days 2, 3 and 4 post-infection. No virus was
detected in oral swabs at any time. Virus was only detected in whole
blood of two of the eight animals (nos. 203 and 206) at day 4 p.i., with
titres just above the detection limit.In the two animals sacriﬁced at day 4, all tissues and contents of
the small and large intestine as well as the Peyer's patches, mesenteric
lymph nodes and the bile tested positive for RCV-A1 RNA, a
distribution similar to that described in wild rabbits (Strive et al.,
2009) (Fig. 2). In comparison, in the two individuals sacriﬁced after
day 7, the virus was absent from the distal part of the small intestine
(ilium) and the caecum and also from the faecal pellets of rabbit no.
207 (data not shown). Virus was absent from the lung, heart, kidney,
tonsils and bonemarrow in all four rabbits. The amount of viral RNA in
the bile was increased approximately tenfold when compared to the
animals sacriﬁced at day 4 p.i. (Fig. 2). Only in animal no. 207 were
low levels of viral RNA detected in the liver.
Low to medium amounts of RCV-A1 RNA were also detected in the
bile of the two rabbits infected with RCV-A1 for serum production at
autopsy, 2 months after the last oral boost infection and 5 months
Fig. 2. Viral RNA load in tissues of rabbits infected with RCV-A1. Quantitative RT-PCR was used tomonitor viral RNA loads in different organ samples of rabbits sacriﬁced 4 and 7 days
post-inoculation with RCV-A1. The dotted line represents the detection limit for the respective tissue sample. ⁎RCV-A1 RNA loads in urine and bile are expressed as log copies per
microliter sample.
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detection limit were also present in the duodenum of both rabbits.
Unexpectedly, no RNA was detected in the liver or faecal samples of
these two rabbits (Fig. 3).
RHDV challenge infection
All animals were challenged with RHDV at day 28 after RCV-A1
infection. The control animals had been housed in the same room. As
it was not clear at the time of challenge if RCV-A1 was possibly
transmitted via aerosols, two new rabbits were introduced to the trial
as additional controls, bringing numbers to n=4 in each group.
Following peroral inoculation with RHDV, all control animals (nos.
194, 196, 205 and 208) were found dead in their cages 2 days post-
challenge infection (d.p.c.). At this time, all animals previously
infected with RCV-A1 were still alive (Table 1).
One animal of the treatment group (no. 209) died 4 days post-
challenge. Autopsy revealed classical macroscopic signs of RHD
(Marcato et al., 1991), such as a friable yellowish liver and enlarged
spleen as well as extensive haemorrhages in the lungs and kidneys.
Animal no. 204 developed severe disease symptoms at 5 d.p.c., namely
lethargy, little resistance to handling, weight loss and a short episode
of very high fever followed by a drastic reduction in body temperature
(Fig. 4). This animal also displayed yellow discoloration of the sclera
and iris and a greenish discoloration of the serum, together suggesting
severe icterus and beginning liver failure and was therefore
euthanized. The gross pathology of the lung, liver spleen and kidneyFig. 3. Long-term persistence of RCV-A1 RNA in rabbit bile. Quantitative RT-PCR was
used to monitor viral RNA loads in different organ samples of rabbits sacriﬁced
16 weeks post-primary inoculation with RCV-A1. The dotted line represents the
detection limit for the respective tissue sample.was similar to animal no. 209 and the control animals, conﬁrming
RHD as the cause of death.
The remaining two animals (nos. 200 and 203) remained healthy
until the trial was terminated 10 d.p.c. All organs of both individuals
appeared macroscopically normal at autopsy. The lungs appeared
uniformly pink, the liver dark and glossy and uniformly coloured and
the spleens were normal in size. All four animals of the treatment
group showed short increases in body temperature to varying
degrees, including the two animals surviving the challenge (Fig. 4).
Faecal samples were analysed for RHDV shedding in the
challenged animals. At the point of death (2 d.p.c.), all control animals
had moderate amounts of viral RNA in faecal pellets (104 to 106
genome equivalents/g faeces). None of the animals that had
previously received RCV-A1 showed any signs of RHDV shedding
in the faeces, including animal no. 209 that succumbed to infection
4 d.p.c. and rabbit no. 204 that was euthanized 5 d.p.c (Fig. 5A). Very
high levels of RHDV-RNA (1010 copies/ml) were detected in the blood
of the control animals at point of death. Viral RNAwas also detected in
the blood of the treatment animal nos. 209 and 203 at 2 d.p.c. At
4 d.p.c., all treatment animals had detectable RHDV-RNA in the blood.
The levels were lowest in the surviving animal nos. 200 and 203 and
higher in the treatment animal nos. 204 and 209 that did not survive,
although not as high as in the blood of the control group animals
(Fig. 5B).
The four control animals were positive for RHDV-RNA in all tissue
samples tested (Fig. 6A). As described in previous studies, the highest
amounts of viral RNA were found in tissues of the liver, spleen and
lung (Shien et al., 2000). A similar distribution was observed in rabbit
no. 209, although amounts were consistently lower when compared
to the control animals, and no RHDV-RNA was detected in the faeces.
Rabbit no. 204 also tested positive in all tissues except faeces, loads
were again reduced in this animal when compared with no. 209,
except in the liver, lung spleen and duodenum, where levels were
comparable as well as in the caecum and mesenteric lymph nodes,
where they were slightly higher. In the surviving rabbit no. 200 RHDV,
RNA levels were further reduced in the liver and spleen. Very low
levels were detected in the heart, lung, kidney as well as mesenteric
lymph nodes and Peyer's patches and the bile. No RNAwas detected in
the small or large intestine, faeces, urine, tonsils or bone marrow. In
animal no. 203, RHDV-RNA was only detected at very low levels in
the liver, spleen and bile and also at moderate levels in the jejunum
(Fig. 6A). When tested for residual RCV-A1, the surviving animal nos.
200 and 203 also still had low amounts of RCV-A1 RNA in the
duodenum, jejunum, appendix, spleen, mesenteric lymph nodes and
Table 1
Experimental outline of the RCV-A1 infections and subsequent RHDV challenge.
Italics indicate control animals. Asterisk indicates animals introduced into the trial at the time of RHDV challenge (day 28).
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post-RCV-A1 infection (Fig. 6B).
Serology
RCV-A1 has only recently been described, and no speciﬁc ELISA
test is available yet. Therefore, four different ELISAs for RHDV were
used to monitor the development of the antibody responses cross-
reacting to RHDV. Until day 4 post-infection, the data show the
absence of any serological response in all eight animals infected with
RCV-A1 (Table 2). Between days 7 and 9 post-infection, cross-reacting
IgM and IgA subclass antibodies became detectable. IgM was present
in three of the six animals treated with RCV-A1 on day 7 post-
infection. Rabbit no. 200mounted a detectable IgM response by day 9.
IgM antibodies declined andwere undetectable by day 14 in rabbit no.
200 and by day 28 in rabbit no. 203. No IgM antibodies were
detectable in the two animals that did not survive the challenge.
Similarly, IgA antibodies were detectable in the same three
animals out of the six treated on day 7 post-infection. Rabbit no.
200 mounted a detectable IgA response by day 9 post-infection.Fig. 4. Body weights and rectal temperatures of rabbits following RHDV challenge infection.
challenge are depicted in grey, treatment animals not surviving RHDV challenge have whitAnimal no. 204 also had low-level IgA antibodies detectable between
days 11 and 28. IgA remained detectable in no. 200 until day 28 and
was detected throughout the trial in rabbit no. 203. IgG antibodies ﬁrst
became apparent in rabbit no. 203 by day 9 and were detectable in all
animals infected with RCV-A1. IgG titres were low except for rabbit
no. 203, which mounted medium IgG titres cross-reacting to RHDV.
The two animals that survived the RHDV challenge showed a strong
boost in titres of all subclasses of antibodies. Very high titres of IgM,
IgA and IgG were observed days 35 and 38 in the two surviving
animals, which corresponds to days 7 and 10 post-RHDV challenge.
This indicates that RHDV was clearly capable of infecting these
animals and virus replication took place, which is also supported by
the ﬁnding that RHDV-RNA was detected in the blood at 4 d.p.i.
(Fig. 5B). Throughout the trial, the results of the subclass antibody
tests were reﬂected in the cELISA results, except for animal no. 200,
which was negative in the cELISA test between days 14 and 30 post-
infection, and animal no. 209, which had low levels of cross-reacting
IgGs but no detectable cELISA response. This can be explained by the
nature of this test, where the intact antigen (inactivated viral
particles) is covered by serum antibodies that prevent binding andControl animals are depicted in black symbols. Treatment animals surviving the RHDV
e symbols.
Fig. 6. Viral RNA loads in rabbit tissues following RHDV challenge. Quantitative RT-PCR was used to monitor RNA in different organ samples postmortem. ⁎RNA in urine and bile is
expressed as log copies permicroliter sample. The dotted line represents the detection limit for the respective tissue sample. (A) RHDV-RNA load in rabbit tissues. The values for the 4
control animals are depicted as means plus minus standard deviations. Individual values are depicted for the treatment animals. (B) RCV-A1 RNA loads in tissues of the two animals
surviving the RHDV challenge.
Fig. 5. Virus shedding of rabbits following RHDV challenge infection. Quantitative RT-PCR was used to monitor RHDV-RNA in (A) faecal material and (B) whole blood. RHDV
challenge was applied perorally day 28 post-RCV-A1 infection (treatments). Control animals had not been exposed to RCV-A1 prior to RHDV infection. The dotted line represents the
detection limit for the respective sample. Animals 200 and 203 (grey symbols) survived the challenge.
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Table 2
Antibody responses in rabbit experimentally infected with RCV-A1 and challenged with
RHDV.
Day RCV-A1 infection RHDV challenge
0 4 7 9 11 14 18 22 28 30 32 35 38
IgM
#194 −
#196 −
#205 − − − − − − − − −
#208 − − − − − − − − −
#209 − − − − − − − − − − −
#204 − − − − − − − − − − −
#200 − − − ± ± − − − − − − +++ ++++
#203 − − + + + + ± D − − − ++ +++
#201 D −
#206 − −
#202 − − ++
#207 − − ±
IgA
#194 −
#196 −
#205 − − − − − − − − −
#208 − − − − − − − − −
#209 − − − − − − − − − − −
#204 − − − − D ± − ± ± − −
#200 − − − ± D D D D D − ± ++ ++++
#203 − − + + + + + + ++ + + ++ +++
#201 − −
#206 − −
#202 − − ±
#207 − − D
IgG
#194 −
#196 −
#205 − − − − − − − − −
#208 − − − − − − − − −
#209 − − − − ± ± ± ± ± ± −
#204 − − − − D + + + + + +
#200 − − − − ± ± + + ++ ++ + +++ ++++
#203 − − − ± + + + ++ ++ ++ ++ ++ ++
#201 − −
#206 − −
#202 − − −
#207 − − −
cELISA
#194 −
#196 −
#205 − − − − − − − − −
#208 − − − − − − − − −
#209 − − − − − − − − − − −
#204 − − − D D D D − D D D
#200 − − − D D − − − − − ± + ++
#203 − − ± ± ± ± ± D ± ± ± + +
#201 D −
#206 − −
#202 − − ±
#207 − − ±
Sera were collected at the indicated time points and analysed using subtype IgG, IgA
and IgM ELISAs as well as a cELISA speciﬁc for RHDV.
Table 3
Long-term IgG antibody responses of rabbits infected twice with RCV-A1.
Weeks post-infection RCV-A1 infection RCV-A1 boost
0 4 9 12
#243 − + ++ ++
#246 − + ++ +++
130 T. Strive et al. / Virology 398 (2010) 125–134detection. As the antigen is not bound to the solid phase, distortion
and exposure of internal epitopes is avoided, thus making this test
more speciﬁc and resulting in less cross-reactivity. None of the four
control animals mounted a detectable antibody response in any of the
ELISAs.
The developing antibody titres of the two rabbits used for anti-
RCV-A1 serum production were also monitored at weeks 4, 9 and 12
post-infection. As serum samples were only collected at monthly
intervals, IgA and IgM were not tested. IgG antibody titres kept
increasing during the 3 months following initial infection, and a
further increase in titres was observed after boost infection, reaching
moderate to high antibody titres at 12 weeks post-infection (Table 3).Discussion
RCV-A1 causes a non-pathogenic infection and is transmitted via the
faecal–oral route
This study delivers the experimental proof that the viral RNA
detected and characterised in previous studies (Strive et al., 2009)
indicated the presence of an infectious virus which causes an entirely
non-clinical infection in rabbits. Although recent progress was made
towards developing reverse genetics system for RHDV (Liu et al.,
2008), lagoviruses including RCV-A1 do not readily grow in cell
culture and therefore plaque assay titration of infectious virus is not
possible. Measuring viral RNA loads was therefore used to study the
course of infection and virus shedding.
The data indicate that RCV-A1 is an enteric virus that is cleared by
the adaptive immune system from day 7 onwards. In RCV-A1-infected
rabbits, viral RNA was present in tissues and contents of the small and
large intestine, aswell as thedraining lymphnodes, the Peyer's patches
and the bile at day 4 p.i. At day 7 p.i., viral RNA had disappeared from
the distal small intestine and the large intestine. Trace amounts of RNA
were detected in the liver in only one animal. This conﬁrms previous
analyses of tissue distributions of RCV-A1 inwild caught rabbits aswell
as observations made in animals infected with the non-pathogenic
Italian lagovirus (RCV-It). For RCV-It, a limited number of different
tissueswere analysed, but similar to RCV-A1 viruswasmainly detected
in the small intestine of all rabbits as well as in the spleen, airways and
liver of some of the rabbits tested by standard RT-PCR and southern
blot (Capucci et al., 1996). Similar to RCV-It, the tissue distribution of
RCV-A1differs signiﬁcantly fromRHDV,which canbe found invirtually
all tissues at very high concentrations, with the highest loads in liver
and spleen (Gall et al., 2007; Shien et al., 2000).
Virus shedding of RCV-A1 was observed in faecal pellets between
days 2 and 7 post-infection. While some of this viral RNA may have
represented residual inoculum from the oral infection, the total
amount of RNA detected in faeces and rectal swabs exceeded the input
RNA amount by several orders of magnitude and clearly indicated
productive viral replication. Rectal swabs were demonstrated to be an
alternative reliable sample for detection of virus shedding. This is an
important ﬁnding for future studies where rabbits are housed in
groups and sampling of individual faecal pellets is not possible as well
as in situationswhere non-invasive sampling of rabbits is needed, such
as capture–mark–recapture experiments of wild rabbits. The decrease
of RCV-A1 RNA in the faeces coincides with the absence of viral RNA
from tissues of the large and distal small intestine as well as the onset
of detectable antibody responses (see below). The results also indicate
that transmission of RCV-A1 occurs via the faecal–oral route, similar to
RCV-It, which had been shown to effectively spread through a rabbitry
via contaminated bedding material and other fomites (Capucci et al.,
1997). Aerosol transmission of RCV-A1 can be considered unlikely, as
no virus was detected in the lungs or oral swabs at any time, and
control rabbits housed in close proximity, but in separate cages to
infected rabbits for a period of 28 days did not acquire the infection.
RCV-A1 RNA is excreted in the bile 2 months after infection
The most surprising ﬁnding of this study was that virus is shed in
the bile of infected animals, and that viral RNA is detectable in the gall
bladder ﬂuid for prolonged periods of time. RCV-A1 RNA was present
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increasing tenfold by 7 days post-infection. In the two rabbits that
were infected with RCV-A1 twice for antiserum production (nos. 243
and 246), moderate amounts of viral RNA (2.5×103 to 3.5×103 copies
per microliter) were still detectable in the bile and duodenum
2 months after the second boost and 4 months after the initial
infection. Similarly, in the bile of the two animals that survived the
RHDV challenge (nos. 200 and 203), there still was RCV-A1 RNA
present 38 days post-initial RCV-A1 inoculation. The presence of
Lagovirus–RNA in the bile has been reported previously. Gall et al.
(2007) found viral RNA in the bile of rabbits naturally surviving an
RHDV infection. However, they could not detect viral antigen in
capture-ELISAs or immunohistochemistry assays, indicating that the
RNA they detected most likely originated from immunocomplexes
(ICs) of RHDV particles and antibodies (Gall et al., 2007).
Bile is produced in the liver, transported through the caniculi into
the bile duct and is then stored in the gall bladder and released into
the duodenum. It plays a vital role in mucosal immunity and contains
high levels of antibodies, in particular IgA. In rabbits, the hepatobiliary
route functions as an additional way to secrete IgAs into the small
intestine. Dimeric IgA reaches the liver through the sinusoids and is
subsequently transported into adjacent bile canaliculi via transcytosis
of poly-Ig receptor-expressing cells (Brown and Kloppel, 1989;
Reynoso-Paz et al., 1999). It is feasible that the RCV-A1 RNA detected
in the bile in this study similarly originates from immune complexes.
This could explain the presence of RCV-A1 RNA in the bile 7 days and
2 months after infection. However, it does not explain the high levels
of RCV-A1 RNA in the bile at day 4 p.i. At this time, no speciﬁc
circulating antibodies are present, and as the bile is a cell-free
environment rich in RNAses, it is likely that the source of the viral RNA
in the bile are free viral particles that protect it from degradation. In
this context, it is surprising that viral RCV-A1 RNA is only rarely
detected in the liver, even with highly sensitive real-time PCR
methods. Very low levels were found in the liver of one rabbit
sacriﬁced at day 7, but not in the livers of rabbits that were sacriﬁced
at day 4 or the two rabbits used for antibody production and sacriﬁced
after 4 months (Fig. 3). Similarly, only one out of three wild caught
rabbits had low amounts of RCV-A1 in the liver (Strive et al., 2009)
and Capucci et al. (1996) only detected RCV-It RNA in the liver of one
out of ﬁve animals tested.
Several interpretations of these ﬁndings are possible, the simplest
being that the liver tissue samples were contaminated with bile
during sampling, although this leaves the question how the virus
reached the bile in the ﬁrst place. In our study, RCV-A1 viral loads
were highest in the bile and then decreased along the small intestine,
with highest concentrations in the proximal part, and lower
concentrations or no virus in the distal part, only to then re-appear
at sites containing faecal material. Although the biliary tract exits into
the duodenum and can periodically be colonized by microbes from
the gut lumen (Chen et al., 2008), it appears unlikely that large
amounts of virus would move upwards from the small intestine
through the bile duct to be concentrated in the bile.
Interestingly, Shien et al. (2000) show that RNA of pathogenic
RHDV is also detected in the bile, but not the liver of young
unsusceptible rabbits at 47 days post-infection, while in adult rabbits
presence of RHDV-RNA in the bile always coincides with detectable
RHDV-RNA in the liver and spleen (Gall et al., 2007; Gall and
Schirrmeier, 2006; Shien et al., 2000). Prieto et al. (2000) reported
that immunolabelling of viral capsid protein was either absent or very
rare in the liver of young rabbits, while very common in adults. Other
studies show that RHDV infections of young rabbits under 8 weeks of
age leads to a very focal and localized mild inﬂammation of the liver
(Ferreira et al., 2006; Ferreira et al., 2005). If the distribution of RCV-A1
is similar, it is feasible that the tissue samples used for RNAdetection in
this study did not contain any of these infected foci. Future studies are
clearly justiﬁed to identify the sites of primary replication and todetermine if the presence of RCV-A1 RNA 2 months after infection is
due to a prolonged or persistent infection of the hepatobiliary system,
or just indicative of a slow clearance from the system.
RCV-A1 infection results in an antibody response cross-reacting to RHDV
and can protect from lethal RHD
No speciﬁc serological tests are currently available for RCV-A1.
However, the partial genetic and antigenic relation between the two
lagoviruses allows the use of the RHDV-speciﬁc ELISAs to study the
main aspects of seroconversion induced by the RCV-1 infection.
RHDV-speciﬁc ELISA tests have also been used extensively for ﬁeld
epidemiology studies in the past and consistently supported the
hypothesis of non-pathogenic related viruses circulating in the ﬁeld
(Cooke et al., 2002). Indeed, despite of the implicit limitations of the
RHDV tests used for monitoring RCV-A1 antibodies, they allowed the
detection of a typical serological response to infection with IgM and
IgA appearing as early as 7 days post-infection, IgM becoming
undetectable after 2 to 3 weeks and IgG developing from day 11
onwards.
The animals treated with RCV-A1 varied in terms of their ability to
withstand RHDV challenge infection. Of the four rabbits previously
infectedwith RCV-A1, one survived the challengewithout any signs of
disease, the second survived but with a short episode of fever. A third
rabbit was euthanized as it developed clinical signs of severe hepatitis,
similar to those described in domestic rabbits following infection with
low doses of German RHDV ﬁeld isolates (Teifke et al., 2002). The
fourth rabbit died shortly after the onset of fever without any other
obvious signs of disease, albeit 96 h post-challenge which is unusually
long when compared to the control animals which all died within
48 h. While the small numbers of animals used in this study do not
allow statistically signiﬁcant conclusions, the results suggest that the
amount of antibodies cross-reacting to RHDV may be correlated with
the chances of survival. Animal no. 209 that died 4 days post-
challenge had only very low levels of cross-reacting IgG antibodies,
and no detectable IgA and IgM responses. Viral loads in the tissues of
this animal were comparable to that of the control rabbits. Animal no.
204 had slightly higher antibody titres than animal no. 209 and also a
low-level detectable IgA response. This rabbit appeared able to ﬁght
the infection for longer, developing a prolonged form of RHD and an
apparent severe hepatitis. This rabbit was euthanized due to animal
ethics regulations; however, it is not impossible that it would have
survived. It has been reported that sometimes individuals can recover
from RHD after a period of lethargy lasting between 4 and 7 days post-
infection, similar to that observed in this study (Capucci, personal
communication). RHDV amounts in the tissues of this rabbits were
clearly reduced when compared to the controls and no. 209,
suggesting that the extent of viral replication was either curbed or
beginning to clear due to adaptive immune responses. Rabbit no. 200
developed a fever and survived the challenge infection; this animal
had antibodies somewhat similar to no. 204, except that it also
showed a detectable IgM response. The rabbit that appeared to be
completely unaffected by the RHDV challenge, no. 203, consistently
had the highest antibodies cross-reacting to RHDV, and all subclasses
were detected. IgM antibodies were only detected in the two
individuals surviving the challenge, suggesting that the development
of a cross-reacting IgM response may be an indicator for the ability of
the rabbit to quickly mobilize and effective immune response
following RHDV challenge.
While the cross-reacting antibodies appeared to protect the
surviving rabbits from disease, they clearly did not protect from
infection. Rabbit no. 200 respondedwith a fever 4 days post-challenge,
coinciding with the presence of viral RNA in the blood. In addition,
both survivors received a boost in antibody titres to RHDV, indicating
productive viral replication. In addition, low levels of RHDV-RNAwere
detected in most tissues of the survivor no. 200 at 10 days post-
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indicating that at least some virus replication, but not dissemination
and high-level replication of RHDV had occurred. Moderate levels of
RHDV secretion through the bilewere detected. This is partly similar to
ﬁndings reported from rabbits vaccinated against RHDV thatwere also
protected from fatal disease, but not from infection. Interestingly, viral
RNAwas absent from the bile of most animals in this study by Gall and
Schirrmeier (2006), although animals were investigated at much later
stages post-challenge (9 to 15 weeks).
The results of this pilot study show that cross-protection from
lethal RHDV is possible, but the protection is not complete. In this
respect, RCV-A1 differs from the Italian RCV, which in an experimental
study protected 100% of rabbits from subsequent lethal RHDV
challenge. These rabbits consistently had cELISA titres between
1:160 and 1:320 as a result of RCV-It infection, similar to vaccinated
rabbits and young rabbits after mild RHDV infection (Capucci et al.,
1996) whereas the cELISA titres in the RCV-A1 infected rabbits in this
study were much lower (Table 2). These differences can be explained
by the consistent differences in antigenic make-up of the non-
pathogenic caliciviruses. The most variable region of calicivirus capsid
protein (E-region) is 68% identical between RCV-A1 and RHDV, with
amino acid changes evenly distributed throughout the protein. In
contrast, the RCV-It shares 85% identity with the RHDV P2 domain and
large stretches of the peptide are identical, increasing the probability
of shared epitopes. In comparison, EBHSV and RHDV share only 53% in
this region of the capsid, and Lavazza et al. (1996) showed that
vaccination with EBHSV did not protect rabbits from RHDV nor did
RHDV vaccination protect hares from EBHS.
Due to the limited epitopes shared between the two viruses, the
proportion of antibodies against RCV-A1 that cross-react to RHDV
epitopes can be presumed to be only a small subset of the total
antibodies produced following RCV-A1 infection. As the amount and
type of antibodies produced vary between individual rabbits, this
may explain the differences in antibody responses in the animals
observed in this study. Only rabbits able to produce a signiﬁcantly
cross-reacting response reach the minimal level of protective
antibodies sufﬁcient to be protected from the disease. This is also a
further demonstration that even low levels of protective antibodies,
in this case produced towards a very limited number of epitopes, are
able to protect rabbits. A possibility that also needs to be considered
is that protection may not be related to cross-reacting antibodies at
all but could be a result of the elevated innate immune competence
following primary RCV-A1 infection. Additional investigations using
larger numbers of rabbits are needed to provide statistically
meaningful information about if and how protection from RHD is
linked to antibody responses and to shed more light on the degree of
individual variation. Future trials also need to take into account
contact infection to mimic more natural routes of acquiring the
infection and address potential effects of neutralising antibodies as
well as dose dependent effects.
Epidemiological relevance of the ﬁndings
The ﬁndings generated in this study are of wide ranging
signiﬁcance for the epidemiology of the two caliciviruses in wild
Australian rabbits. One ﬁnding that contrasts previous assumptions is
the presence of cross-reacting IgA and IgM antibodies as a result of
RCV-A1 infection. Previous classiﬁcation systems used to estimate the
prevalence of RCV-A1 in wild Australian rabbits scored all animals
with either IgA or IgM antibodies as positive to RHDV (Cooke et al.,
2000), mainly due to the fact that in sera collected in Australia pre-
RHDV release, IgA and IgM were rarely detected. However, our study
shows that the window for cross-reacting IgA and in particular IgM
responses may be so short that they simply went unnoticed. Thus, the
prevalence of RCV-A1 in wild rabbit populations may have been
underestimated.The presence of RCV-A1 is very likely to promote the increase of
wild Australian rabbit populations and the reduction of RHDV
effectiveness in controlling rabbits. During an epidemic, RHDV causes
onlymild liver infections in young rabbits (Ferreira et al., 2006;Mikami
et al., 1999) and usually leads to seroconversion to RHDV (Robinson
et al., 2002b). When reaching sexual maturity, these rabbits will
become part of the RHDV resistant breeding population. RCV-A1
infectionmay cause a similar effect in older rabbits thatwouldnormally
be susceptible to lethal RHD. These cross-vaccinated animals may only
develop mild, if any symptoms, survive the infection with very high
anti-RHDV antibody titres and join the RHD resistant breeding
population. Previous work studying fertility control of feral rabbits
have shown that the breeding of at least 80% of the femaleswould have
to be suppressed tomaintain rabbit numbers belowdamage thresholds
(van Leeuwen and Kerr, 2007). In the light of these ﬁndings, it appears
that even if the amount of additional RHDV resistant adults due to
cross-protection from RCV-A1 is low, due to the enormous fecundity of
rabbits this is likely to have a measurable effect on rabbit numbers.
Interestingly, RHDV-RNA was never detected in the faeces of
rabbits previously infected with RCV-A1, regardless if they survived
the RHDV challenge or not. This indicates that these rabbits do not
represent a likely additional reservoir for infectious RHDV during an
RHDV epidemic, at least not for the direct contact route of infection.
However, the RHDV concentration in most tissues of the animals that
died from RHDV was comparable regardless of previous RCV-A1
infection. This indicates that distance transmission of RHDV, which is
thought to be mainly a result of mechanical transmission by ﬂies that
feed on rabbit carcasses (Asgari et al., 1998; McColl et al., 2002; Ward
et al., in press), can still originate from rabbits previously infected
with RCV-A1. Screening of wild Australian rabbits needs to continue
in order to shed light on the epidemiology of both RCV-A1 and RHDV
and to also to keep searching for potential additional RCV-A1 strains
with different biological and cross-protective properties that may
co-circulate among wild rabbits.
How does RCV-A1 maintain itself in the population? As the main
route of transmission of RCV-A1 appears to be faecal–oral, rabbit
demographics could give a simple explanation. Past studies show that
the presence of cross-reacting antibodies appear to be more common
in temperate climate zones of the Australian continent, where rabbit
reproduction is less seasonal (Cooke et al., 2002) and year-round
breeding can occur (Richardson et al., 2007). Year-round breeding
would provide a constant supply of new susceptible individuals that
could carry the infection.
However, the prolonged presence of RCV-A1 RNA in the bile gives
rise to a second alternative hypothesis. Althoughviral RNA levels in the
bile remain quite high for up to 2months, shedding through the faeces
is only observed between days 1 and 2 post-infection, which coincides
with the ﬁrst occurrence of IgA antibodies. Although only humoral
responseswere investigated, it is reasonable to assume that the timing
of mucosal secretory IgA production is similar and that secretory IgA
may play a vital role in curbing viral shedding. Future studies are
needed to investigate the duration of RCV-A1 shedding through the
bile and to address if a decrease inmucosal soluble IgAswill render the
carrier animals infectious again. The possibility of persistent RCV-A1
infection of the hepatobiliary system that can re-start the infection in a
population by a natural decline of mucosal antibodies, or following
immune suppression triggered for example by breeding and pregnan-
cy, is an interesting possibility.
It is generally accepted that the pathogenic forms of RHDV have
emerged from non-pathogenic forms of caliciviruses infecting rabbits
through mutation (Capucci et al., 1996; Forrester et al., 2006; Kerr
et al., 2009); however, the mechanisms leading to such a dramatic
change in pathogenicity and tissue tropism are not understood.
Studies of non-pathogenic relatives of RHDV therefore represent an
excellent opportunity to investigate the underlying molecular and
immunological mechanisms and the evolution of this disease.
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Animal husbandry, experimental infections and sampling
Thirteen-week-old New Zealand White rabbits were used for
infection with RCV-A1 and subsequent RHDV challenge (refer to
Table 1 for experimental design). Rabbits were housed individually in
cages of 84×60×63 cm. All animals had ad libitum access to water
and commercial rabbit pellets throughout the entire experiment.
For the infection with RCV-A1, gut homogenate derived from a
wild rabbit that had tested PCR positive for RCV-A1 (Strive et al.,
2009) was clariﬁed by centrifugation at 3000 g for 15 min. The
genome equivalents of the supernatant were determined using qRT-
PCR (see below) and adjusted to 108 copies/ml by adding PBS. Eight
rabbits were inoculated perorallywith 1ml of this suspension. Control
rabbits (n=2) received 1 ml PBS via the same route (see Table 1 for
experimental design). Animals were monitored daily. Blood, faecal
pellets, oral swabs, rectal swabs as well as body weights and rectal
temperatures were taken daily during the ﬁrst 4 days and then on
days 7, 9, 11, 14, 18, 22 and 28. Bloodwas collectedwith a heparinized
syringe from the marginal ear vein and centrifuged for 5 min at
9000×g to separate the plasma. Sixty microliters of whole blood was
used for RNA extraction (see below). Oral and rectal swabs were
collected using sterile cotton buds. Swabs were soaked in 1 ml PBS for
2 h at 4 °C and the resulting suspension used for RNA extraction. For
the daily collection of pellets, clean paper sheets were placed under
the cages the night before the sampling day and droppings collected
the following morning. Two of the RCV-A1 inoculated animals were
euthanized at days 4 and 7, respectively, for analysis of tissue
distribution in the infected host and to generate more virus material
for future studies. Rabbits were anaesthetized by injecting a 1:1
mixture of 20 mg/ml xylazine–HCL and 100 mg/ml ketamine–HCL
intramuscularly at a concentration of 0.3 ml/kg body weight, and
subsequently euthanized by intra-cardiac injection of sodium pento-
barbitone, 1 ml/kg body weight.
Samples collected at autopsywere lung, liver, spleen, heart, kidney,
duodenum, jejunum, ilium, caecum, appendix, Peyer's patches,
mesenteric lymph nodes, tonsils, bone marrow, faeces and urine.
For the RHDV challenge infection, two additional control rabbits
were added to the trial. All control rabbits and the remaining four
rabbits previously inoculated with RCV-A1 were perorally infected
with 1 ml of commercially available RHDV preparation containing
500 LD50 (RCD batch 1a, Elizabeth McArthur Agricultural Institute,
Menangle, Australia). Following RHDV challenge, rabbits were
monitored twice daily for signs of terminal disease, indicated by
lethargy, loss of appetite and little resistance to handling. Blood, faecal
pellets and body weights were collected on days 28, 30, 32, 35 and 38;
and a ﬁnal blood sample was collected postmortem in animals that
did not survive the challenge. Rectal temperatures were taken twice
daily until day 34 and then daily until day 38. Rabbits surviving the
challenge were euthanized as described above. All rabbits were
autopsied and the sample set described above was collected.
In a separate experiment, two naïve 12-week-old NZ white rabbits
were perorally infected with 107 genome equivalents of RCV-A1 and
boosted once with the same peroral dose at 3 months post-primary
infection, with the aim of producing reference sera positive to RCV-A1
only, for future serology studies. The inoculum for these rabbits was
homogenized duodenum from a rabbit from the above described
experiment that was sacriﬁced 7 d.p.i. (no. 207) at a concentration of
107 genome equivalents per dose. Seven weeks after the boost
(16 weeks post-primary infection), these animals were anaesthetized
and euthanized as described above. Approximately 200 ml of blood
was collected directly from the heart, and duodenum, bile, faecal
pellets and liver tissues were collected at autopsy. Serum samples
were collected from these rabbits at time of infection, and then at
weeks 4, 9, 12 and 16.All procedures involving live animals were conducted according to
the Australian code of practise for the care and use of animals for
scientiﬁc purposes and were approved by the CSIRO Sustainable
Ecosystems Animals Ethics Committee (SEAEC no. 08-02).
Sample processing for different tissues
RNA was extracted from 250 μl bile, urine and swabs using Trizol
LS (Invitrogen), according to the instructions of the supplier. Glycogen
(20 μg per sample) was added as a carrier. Tissue samples and blood
were extracted using the QIAGEN RNEasy kit following the suggested
protocols. The weights of the tissue samples used for RNA extractions
were recorded.
Detection of viral RNA
The real-time PCR assay, primers, standards and conditions for
RCV-A1 have been described elsewhere (Strive et al., 2009). For the
detection of RHDV-RNA, primers RHDV-RT2-fw (5′-ACCCAGTACGG-
CACRGGCTCCCAACCAC-3′) and RHDV-RT2-rv (5′-CTATCTCCAT-
GAAACCAGATGCAAAGG-3′) were used with the Quantitect SYBR
green RT-PCR kit (QIAGEN) according to the instructions of the
supplier. To obtain standards for RHDV, the capsid sequence was
ampliﬁed from a rabbit experimentally infected with the commer-
cially available RHDV strain (RCD batch 1a) using primers pRHDV
capsid fw (5′-AAAAGCTTATGGAGGGCAAAGCCCGTGCAGC-3′) and
RHDV capsid rev (5′-AAGCGGCCGCATTGCTCAGGACACCGGCACC-
TGC-3′) and cloned into pCDNA3 (Invitrogen) via NotI and HindIII.
The plasmid was linearized with NotI and runoff transcripts were
produced from the T7 promoter using the Riboprobe in vitro
transcription kit (Promega) according to the instructions of the
manufacturer. Transcript concentration was measured photometri-
cally, the copy number determined using the formula provided by the
supplier and serial dilutions were used as standards in real-time PCR.
The detection limit for RHDV-RNA was 20 copies per reaction.
Serology
RHDV antibody titres were measured semi-quantitatively using
a competition ELISA (cELISA) and three isotype ELISA's designed to
detect RHDV antibody isotypes for IgG, IgA and IgM as previously
described (Capucci et al., 1996, 1991; Cooke et al., 2000) but with
minor modiﬁcations. The cELISA measured antibody levels at four
serial dilutions, (1:10, 1:40, 1:160, 1:640). The isoELISAs measured
antibody isotypes for IgG, IgM and IgA using six serial dilutions,
(1:40, 1:160, 1:640, 1:2560, 1: 10240 and 1:40960). For sera with
titres N1:40960, additional dilutions were tested to determine the
ﬁnal titre. Sera were considered positive in cELISA if the OD492
value was lower than the OD492×0.75 of the negative reference
sera at a 1/10 dilution. The titre of each positive serum was taken
as the dilution that reduced the OD492 by 50% compared with the
initial wells of the negative reference sera. For the IgG, IgM and
IgA isoELISAs, sera were considered positive if the OD492 value at
the 1/40 dilution was more than twice the OD value of the
negative serum dilutions used as controls. The titre of the positive
samples was then determined using the dilutions steps described
above.
Positive samples were scored as follows: D=doubtful, ± (positive
at dilution 1:40),+ (1:160 to 1: 640),++(1:2560 to 1:10240),+++
(1: 40960 to 163840) and ++++ (1:655360 and higher).
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